Imagion CEO Bob Proulx discusses the company’s path to first-in-human trials plus early discussions with potential partners and strategic investors in this Margermarket article.
Read the article.
Corporate Update – IND for MagSense® HER2 Phase 2 Study Immediate Priority
Corporate Updates: $3M fundraising led by CPS Capital to be completed in early December Filing of IND for MagSense® HER2 Phase 2 Study Immediate Priority